HB910 establishes a Rare Disease Advisory Council within the Department of Health to advise the legislature, state agencies, and the public on the needs of people living with rare diseases in Hawaii. The council would conduct a statewide needs assessment, consult experts, recommend policy changes, identify research gaps, distribute educational resources for providers, and propose ways to improve diagnosis, treatment, health equity, and access to specialists and medications. It would also maintain a public website, hold regular meetings, and submit annual reports with findings and proposed legislation.
The bill also makes related changes outside the council structure. It directs the Department of Health and the Department of Education to include information on the importance of annual physical exams for children in public health and school-related communications. In addition, it amends Hawaii’s insurance law to require coverage for medically necessary orthodontic services for orofacial anomalies and velocardiofacial anomalies, including conditions associated with 22q11 deletion syndrome/DiGeorge syndrome, and bars cost-sharing for that coverage. The bill appropriates $50,000 for each of fiscal years 2025-2026 and 2026-2027 to establish and operate the council, and creates a special fund for grants and other outside funding.
The bill’s impact on state law would be to add a new advisory body to Chapter 321 of the Hawaii Revised Statutes, expand public-health messaging duties for DOH and DOE, and revise the insurance code to broaden mandated coverage for certain craniofacial and genetic-disorder-related orthodontic treatment. It would affect state agencies, insurers, health plans, patients with rare diseases, caregivers, providers, researchers, and families of children with velocardiofacial syndrome or related anomalies.
The available context suggests generally favorable policy intent, with the bill framed as a public-health and patient-support measure. There are no recorded committee transcripts or votes in the provided materials, so there is no direct evidence of opposition or support from legislators in the record supplied. The bill’s findings emphasize unmet medical needs, diagnostic delays, and access barriers, indicating a strong advocacy-oriented rationale.
The main points of potential contention are likely to be the new state spending, the administrative burden of creating and staffing the council, and the insurance mandate requiring coverage without cost sharing. Another possible issue is the breadth of the council’s membership and the involvement of insurers, biopharma, and patient advocates in shaping recommendations. However, no specific objections are documented in the provided history.
HB910 would add a new Rare Disease Advisory Council to Hawaii law, require annual reporting and public engagement, create a special fund, and appropriate state general funds for council operations. It would also amend existing health and education statutes to promote annual pediatric physical exams and revise the insurance code to mandate coverage for medically necessary orthodontic services tied to orofacial and velocardiofacial anomalies, including 22q11 deletion syndrome/DiGeorge syndrome, with no copayment, deductible, or coinsurance for that coverage.
The bill appears to have a generally supportive, health-equity-oriented framing, with its findings emphasizing the burdens faced by rare-disease patients and the need for coordinated state action. The provided record contains no committee testimony or vote history, so there is no documented opposition or formal sentiment from legislators in the materials supplied. Overall, the measure reads as an advocacy and access-to-care bill rather than a controversial policy change.
Potential contention centers on the insurance mandate and the fiscal/administrative costs of creating a new advisory council and special fund. Insurers and budget-conscious policymakers could question the required coverage expansion, the exemption from cost-sharing, and the ongoing state appropriation. There may also be debate over whether the council’s recommendations should influence Medicaid and private insurance coverage, but no specific objections are recorded in the provided context.